Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.50 |
| ▸ | PYGM | P11217 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.44 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27830397 | 0.86 | KAT6A (0.44) | KAT6APYGMMEN1KMT2ANPC1 | |
| SCHEMBL2274841 | 0.85 | ACLY (0.54) | KAT6AMEN1KMT2APKMSERPINE1 | |
| SCHEMBL2271446 | 0.84 | PYGM (0.50) | PYGMMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2271350 | 0.80 | PYGM (0.48) | KAT6APYGMMEN1KMT2ANPC1 | |
| SCHEMBL2271588 | 0.80 | SERPINE1 (0.64) | PYGMMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2275060 | 0.78 | AKR1C4 (0.59) | PYGMMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2275544 | 0.78 | FABP1 (0.61) | PYGMMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2273349 | 0.77 | MEN1 (0.61) | PYGMMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2273436 | 0.77 | PYGM (0.70) | PYGMMEN1KMT2ANPC1RAB9A | |
| SCHEMBL2269525 | 0.77 | GRIK1 (0.66) | PYGMMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101094829-B | novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO.,LTD. (JP) | 2012-02-08 | — | — | CN | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | KAT6A 491/4885PYGM 1299/4885MEN1 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.